SIREN : 813979523
VIVALTO SANTE INVESTISSEMENT is a French company founded 10 years ago, specialized in the sector Activités des sociétés holding. Based in PARIS (75016), this company of category GE shows in 2024 a revenue of 10.1 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 10 055 373 € | 8 703 878 € | 8 170 756 € | 5 726 675 € | 4 548 857 € | 3 976 608 € | 2 991 745 € | 2 647 769 € | 2 355 514 € | N/C |
| Net income | -119 805 012 € | -95 129 846 € | -58 642 744 € | -61 365 308 € | -23 199 602 € | -19 124 834 € | -15 431 241 € | -11 759 701 € | -19 363 225 € | 0 € |
| EBITDA | -5 826 929 € | -6 032 368 € | -2 139 780 € | -1 329 431 € | -1 071 564 € | -26 438 € | -808 145 € | -546 228 € | -659 850 € | N/C |
| Net margin | -1191.5% | -1093.0% | -717.7% | -1071.6% | -510.0% | -480.9% | -515.8% | -444.1% | -822.0% | N/C |
In 2024, VIVALTO SANTE INVESTISSEMENT achieves revenue of 10.1 M€. Over the period 2016-2024, the company shows strong growth with a CAGR (compound annual growth rate) of +19.9%. Vs 2023, growth of +16% (8.7 M€ -> 10.1 M€). After deducting consumption (15 k€), gross margin stands at 10.0 M€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches -5.8 M€, representing -57.9% of revenue. Positive scissor effect: EBITDA margin improves by +11.4 pts, sign of improved operational efficiency. Negative EBITDA means operations do not cover current expenses: concerning situation. Net income is negative at -119.8 M€ (-1191.5% of revenue), which will impact equity.
10 055 373 €
10 040 101 €
-5 826 929 €
-10 642 119 €
-119 805 012 €
-57.9%
The debt ratio (= Financial debt / Equity x 100) stands at -3331%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches -3%. Low autonomy: the company heavily depends on external financing (banks, suppliers).
-3331.492%
-3.059%
-917.709%
-24.411
73.1%
In 2024, the debt ratio of VIVALTO SANTE INVESTISSEMENT (-3331.49) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.
In 2024, the financial autonomy of VIVALTO SANTE INVESTISSEMENT (-3.1%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2024, the repayment capacity of VIVALTO SANTE INVESTISSEMENT (-24.41) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.
The liquidity ratio (= Current assets / Current liabilities) stands at 2014.26. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
2014.262
-2391.925
In 2024, the liquidity ratio of VIVALTO SANTE INVESTISSEMENT (2014.26) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
In 2024, the interest coverage of VIVALTO SANTE INVESTISSEMENT (-2391.9x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 40 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 176 days. Excellent situation: suppliers finance 136 days of the operating cycle (retail model). Overall, WCR represents 12435 days of revenue, i.e. 347.3 M€ to permanently finance.
347 335 912 €
40 j
176 j
0 j
12435 j
Based on 54 transactions of similar company sales
in 2024,
the value of VIVALTO SANTE INVESTISSEMENT is estimated at
5 920 318 €
(range 3 683 187€ - 7 038 143€).
The price/revenue ratio is 0.59x
(in line with sector norms).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.
Only this financial indicator is available for this company.
This estimate is based on the analysis of 54 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare VIVALTO SANTE INVESTISSEMENT with other companies in the same sector:
Voir toutes les statistiques du secteur Activités des sociétés holding
The revenue of VIVALTO SANTE INVESTISSEMENT in 2024 is 10.1 M€.
VIVALTO SANTE INVESTISSEMENT recorded a net loss in 2024.
The headquarters of VIVALTO SANTE INVESTISSEMENT is located in PARIS (75016), in the department Paris.
The tax return of VIVALTO SANTE INVESTISSEMENT is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
VIVALTO SANTE INVESTISSEMENT operates in the sector Activités des sociétés holding (NAF code 64.20Z). See the 'Sector positioning' section above to compare the company with its competitors.